Pharmidex Press Page

See below for our latest news!

News

July 28, 2025
We’re delighted to welcome Gabrielle Georgiou and Dr. Mohammed Ahmad from the University of Hertfordshire as they begin their first experience in a scientific CRO environment here at Pharmidex ! This partnership is an exciting step in fostering early-career scientific talent by offering hands-on exposure to real-world drug discovery and preclinical research. A big thank you to the University of Hertfordshire for partnering with us to support the next generation of innovators. We’re proud to play a role in shaping future leaders in science through meaningful, practical learning opportunities. ๐Ÿ‘ฉ‍๐Ÿ”ฌ ๐Ÿ‘จ‍๐Ÿ”ฌ Welcome to the team, Gabrielle and Mohammed!
BATA Taste Aversion
July 24, 2025
At Pharmidex , we offer Brief Access Taste Aversion (BATA) testing, which is a behavioural assay that quantifies how test subjects respond to different compounds or formulations by measuring lick response and aversion. This helps identify: โœ… Bitter-tasting APIs โœ… Unpalatable excipients โœ… The success of taste-masking strategies โœ… Formulation-dependent compliance risks Get in touch if you’re developing oral formulations, paediatric drugs, or repurposing bitter APIs, this could be the data your IND package needs.
July 21, 2025
Pharmidex is proud to offer access to the 8HUM model genetically humanized for 33 liver CYP enzymes responsible for metabolizing 90% of human drugs. โœ… Human-relevant metabolism data โœ… Supports IND-enabling ®gulatory studies โœ… Ideal for metabolite profiling, DDI risk & toxicity assessment By integrating 8HUM into our DMPK and in vivo studies, we deliver deeper, more predictive insights for safer, smarter drug development. ๐Ÿ“ฉ Contact us to see how 8HUM can support your project.
July 17, 2025
We’re growing and looking for passionate scientists to join our dynamic team. If you're excited by impactful science and meaningful collaboration, check out our latest roles: ๐Ÿ”ฌ Bioanalytical Scientist (Permanent) Work with LC-MS/MS platforms to support preclinical and clinical bioanalysis across a wide range of therapeutic areas. ๐Ÿงซ Histology Technician (3-Month FTC, Full or Part-Time) Be at the heart of tissue processing for in vivo and toxicology studies GLP experience welcome, flexibility offered. ๐Ÿงช Scientist / Senior Scientist – Immunology (Full-Time) Advance autoimmune disease research through innovative T-cell and cytokine profiling assays. ๐Ÿ’ก Why Pharmidex? โœ” 20+ years of scientific excellence โœ” Collaborative, science-led culture โœ” Diverse therapeutic expertise โœ” Real-world impact through discovery and development ๐Ÿ“ฉ Ready to apply or want to learn more? Visit www.pharmidex.com/careers or email your CV to [email protected] Applications are reviewed on a rolling basis, early interest encouraged! ๏ปฟ Let’s shape the future of drug discovery together.
harmidex Launches GLP-Validated Intracranial Dosing for CNS Research
July 15, 2025
We’re excited to introduce our GLP-standard intracranial dosing platform delivering targeted compounds directly to the brain for more precise CNS preclinical studies. โœ… Bypasses the blood-brain barrier โœ… Reduces systemic side effects โœ… Enhances translational relevance Now fully GLP-validated with: Documented SOPs & equipment Verified dose placement MHRA-audited compliance ๐Ÿ“ˆ Benefits: Regulatory-ready data, better reproducibility, and lower repeat study costs. ๐Ÿ‘‰ Swipe the carousel to learn more. ๐Ÿ”— www.pharmidex.com
New Insights from Pharmidex: Tumour Microdialysis in Glioblastoma
July 10, 2025
We’re excited to share our latest work on tumour microdialysis, a powerful technique for measuring unbound, pharmacologically active drug concentrations directly within brain tumours like glioblastoma. Unlike systemic plasma levels, microdialysis provides a true picture of drug penetration into the tumour helping to uncover heterogeneous distribution and the impact of the blood-tumour barrier. Our approach involves precise stereotaxic surgery, tumour validation, and sampling from both tumour and healthy brain tissue enabling direct, comparative pharmacokinetic analysis. ๐Ÿ“Š The results? Significant differences in drug exposure between tumour core and surrounding tissue. ๐Ÿ‘‰ Swipe through the carousel to explore our process and findings. ๏ปฟ ๐Ÿ”— www.pharmidex.com
More Posts